Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Conclusion: Clinically meaningful improvements in OS and PFS observed with atezolizumab plus bevacizumab versus sorafenib suggest that atezolizumab plus bevacizumab may become a practice-changing treatment for Chinese patients with unresectable HCC.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | China Health | Hepatocellular Carcinoma | Hypertension | Liver | Liver Cancer | Study | Toxicology | Urology & Nephrology